Zafirlukast

扎鲁司特

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameZafirlukast
Drug Alias NameAzimax扎鲁斯特扎仑司特VanticonAccolate SR +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeukotriene E4 receptor antagonistsCysteinyl leukotriene receptor 1 antagonists
TargetsCysteinyl leukotriene receptor 1Leukotriene E4 receptor
Therapy Area/IndicationsAsthmaOvarian NeoplasmsBreast Neoplasms
Global Approved IndicationsAsthma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1996/09/26
Country/TerritoryUnited StatesIndiaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteStrides Pharma International AgAstrazeneca Pharmaceutical Co Ltd
Inactive CompaniesUniversity Of California San FranciscoDr.Reddy's Laboratories Ltd
Active IndicationsAsthmaOvarian Neoplasms
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeR03DC01
Related LinksWikipediaDrugBankKEGG